Selecting the appropriate transgenic APP mouse model depends on your scientific objectives, target pathway, and required disease kinetics. If your program requires rapid proof-of-concept data, early plaque pathology, and integrated pathology–cognition readouts within a short experimental timeline, double transgenic APP/PS1 models are often preferred due to their accelerated amyloid deposition.  

In contrast, single transgenic APP models such as the APP[V717I] mouse model may be better suited for studies focused on slower, age-dependent amyloid progression, disease modification, or long-term biomarker evolution. 

Beyond pathology onset, practical considerations such as model availability, reproducibility across cohorts, compatibility with behavioral and fluid biomarkers, and historical benchmarking should also guide model selection.  

InnoSer’s team routinely advises on these aspects to ensure that each study is fit-for-purpose rather than model-driven. 

Contact InnoSer’s scientific team to discuss which transgenic APP model best fits your Alzheimer’s disease research strategy. 

Yes, due to the presence of familial Alzheimer’s disease mutations in APP and PS1, single transgenic APP as well as the double transgenic APP/PS1 mouse models predominantly generate the more aggregation-prone Aβ42 species, alongside Aβ40. In APP/PS1 models, mutant presenilin-1 shifts γ-secretase activity toward increased Aβ42 production, resulting in a markedly elevated Aβ42/Aβ40 ratio and earlier plaque formation compared with single APP models. 

In addition to canonical Aβ species, pyroglutamate-modified Aβ (AβpE3–42), a highly pathogenic and aggregation-prone form detected in human Alzheimer’s disease, has also been identified in APPxPS1 models. The presence of these clinically relevant Aβ species enhances the translational value of these models for evaluating amyloid-lowering and plaque-modifying therapies. 

InnoSer’s expert scientific team has performed multiple validation studies, quantifying the levels of amyloid beta species including both soluble and insoluble forms.  

Reach out to our team and receive the validation datasets from your mouse model of interest still today.  

Yes, cerebral amyloid angiopathy (CAA) has been described in multiple APPxPS1 mouse models, including in the ARTE10 line (Willuweit et al. 2009) as well as InnoSer’s APPxPS1 line.  

CAA is a common and clinically relevant cerebrovascular pathology characterized by the accumulation of Aβ peptides within the walls of cerebral blood vessels. CAA is present in a substantial proportion of Alzheimer’s disease (AD) patients and is increasingly recognized as a key contributor to vascular dysfunction, impaired cerebral blood flow, blood–brain barrier disruption, and intracerebral haemorrhage.  

In recent years, interest in CAA has grown markedly as clinical trial outcomes have highlighted vascular amyloid as a potential driver of treatment-related adverse events, including amyloid-related imaging abnormalities (ARIA).  

Consequently, CAA has emerged as an important target for mechanistic studies and for the preclinical evaluation of anti-amyloid therapies, particularly immunotherapies and approaches aimed at improving vascular amyloid clearance. 

Reach out to our team to explore how InnoSer can support the preclinical assessment of cerebral amyloid angiopathy (CAA) and amyloid-related imaging abnormalities (ARIA). 

While APPxPS1 mice develop robust amyloid pathology and dystrophic neurites containing hyperphosphorylated murine tau, they do not recapitulate full neurofibrillary tangle pathology. 

This absence of overt tangle pathology is consistent with other APP/PS1 transgenic mouse models. Amyloid-only models robustly reproduce cerebral beta amyloidosis but do not recapitulate the full spectrum of Alzheimer’s disease encompassing tau pathology. To model both amyloid plaques and neurofibrillary tangles in vivo, the incorporation of mutant human tau is required. 

Therefore, for therapies targeting combined amyloid-and-tau disease modification, we recommend the APP[V717I]xTau[P301S] mouse model, which recapitulates both extracellular amyloid plaques and progressive tau pathology, providing a more complete Alzheimer’s disease phenotype. 

Learn more about InnoSer’s combined amyloid and tau mouse model here.